Published: 2019-11-26

Immunohistochemistry profile and its relation with prognosis in locally advanced breast cancer

Naseef Kannanavil, Nabeel Thommil Padinjarenalakath, Ahsan Vilayapoyilil, Abidali Karatparambil


Background: Breast cancer is one of the most common malignancy and leading cause of cancer related deaths in women worldwide. Immunohistochemistry (IHC) is done to characterize intracellular proteins or cell-surface antigens and is used to assess tumour subtypes, confirm diagnosis, predict prognosis and response to therapy. The aim of the present study was to evaluate the relationship of IHC profile- ER, PR and HER2 neu and prognosis of patients who underwent modified radical mastectomy for locally advanced breast cancer.

Methods: A retrospective cohort study was conducted at MES Medical College Hospital from October 2015 to November 2017 in patients who underwent modified radical mastectomy for locally advanced breast carcinoma. A total of 65 women were enrolled in the study. 5 years survival was taken as the prognostic indicator.

Results: Majority of the patients belong to the age group of 40-49 years with 40% patients followed by 33.84% patients in the age group of 50-59 years. Maximum number of patients was found in 2B stage of tumour. Maximum patients belonged to the ER/PR+, HER2- subgroup (27), followed by triple negative (ER/PR-, HER2) subgroup (16). There was no disease related mortality in ER/PR+, HER2+ and ER/PR+, HER2- subgroups. There were 1 and 2 disease related mortality in ER/PR-, HER2+ and triple negative subgroups respectively.

Conclusions: In the present study the worst prognosis was observed in triple negative (ER/PR-,HER2-) IHC subgroup followed by the HER2 enriched (ER/PR-, HER2+) subgroup.



IHC, Locally advanced breast cancer, Modified radical mastectomy, 5 year survival, Prognosis

Full Text:



Dumitrescu RG, Cotarla I. Understanding breast cancer risk- where do we stand in 2005?. J Cell Mol Med. 2005;9(1):208-21.

Pal SK, Mittal B. Improving cancer care in India: prospects and challenges. Asian Pac J Cancer Prev. 2004;5(2):226-8.

Breast. Globocan. World Health Organization. International Agency for Research on Cancer, 2018. Available at: Accessed on 23 November 2019.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.J ClinOncol. 2007;25(33):5287-312.

IHC tests (Immunohistochemistry). Available at: types/ihc. Accessed on 23 November 2019.

Zaha DC. Significance of immunochemistry in breast cancer. World J ClinOncol. 2014;5(3):382-92.

Khalis M, El Rhazi K, Charaka H, Chajes V, Rinaldoi S, Charbotel B, et al. Female breast cancer incidence and mortality in Morocco: comparison with other countries. Asian Pac J Cancer Prev. 2016;7(12):5211-6.

Lee HC, Ko H, Seol H, Noh DY, Han W, Park A, et al. Expression of immunohistochemical markers before and after neoadjuvant chemotherapy in breast carcinoma, and their use as predictors of response. J Breast Cancer. 2013;16(4):395-403.

Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. J Res Pharm Pract. 2014;3(1):12-8.

Gogia A, Deo SV, Shukla NK, Mathur S, Sharma DN, Tiwari A. Clinicopathological profile of breast cancer: an institutional experience.Indian J Cancer. 2018;55(3):210-3.

Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer. 2010;47(1):16-22.

Ng HS, Vitry A, Koczwara B, Roder D, McBride ML. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control. 2019;30(9):931-41.

Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H, et al. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev. 2015;16(12):4959-64.

Onitilo AA, Engel JM, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13.